Serum CGRP in migraine patients using erenumab as preventive treatment

Simone de Vries Lentsch; Ingrid M. Garrelds; A. H. Jan Danser; Gisela M. Terwindt; Antoinette MaassenVanDenBrink

doi:10.1186/s10194-022-01483-z

The Journal of Headache and Pain (Sep 2022)

Serum CGRP in migraine patients using erenumab as preventive treatment

Simone de Vries Lentsch,
Ingrid M. Garrelds,
A. H. Jan Danser,
Gisela M. Terwindt,
Antoinette MaassenVanDenBrink

Affiliations

Simone de Vries Lentsch: Department of Neurology, Leiden University Medical Centre
Ingrid M. Garrelds: Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC University Medical Center
A. H. Jan Danser: Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC University Medical Center
Gisela M. Terwindt: Department of Neurology, Leiden University Medical Centre
Antoinette MaassenVanDenBrink: Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC University Medical Center

DOI: https://doi.org/10.1186/s10194-022-01483-z
Journal volume & issue: Vol. 23, no. 1
pp. 1 – 7

Abstract

Read online

Highlights • Lower serum levels of calcitonin gene-related peptide (CGRP)-like immunoreactivity (CGRP-LI) in migraine patients at 2–4 weeks after starting treatment with erenumab were associated with better treatment response after three months. • Early changes in serum CGRP may be important for the clinical effect of erenumab in migraine.

Published in The Journal of Headache and Pain

ISSN: 1129-2369 (Print); 1129-2377 (Online)
Publisher: BMC
Country of publisher: United Kingdom
LCC subjects: Medicine
Website: https://thejournalofheadacheandpain.biomedcentral.com/

About the journal

Abstract

Keywords